web currency- Top Knowledge graph

The RMB exchange rate is expected to appreciate again at the end of the year. The research team of the Financial Market Department of Agricultural Bank of China said that the market transactions have shown obvious narrative-driven characteristics in recent years. Considering some recent changes, the RMB exchange rate is expected to stabilize and rebound again in the future. First, the pricing of Trump transactions in the international market has come to an end. Second, there has been a major shift in domestic macro policies. Since late September, financial policies such as lowering the RRR, cutting interest rates, supporting the stock market and the real estate market, and fiscal debt measures have boosted market confidence. Third, there has been a favorable change in supply and demand in the domestic foreign exchange market. The end of the year is the traditional peak season for enterprises to settle foreign exchange, and the continuous forward discount will lead to the backlog of foreign exchange settlement, which will further amplify the demand for foreign exchange settlement at the end of the year. Further considering the overall situation of the game between China and the United States, Trump's return not only means the enhancement of external shocks, but also the upgrading of internal policies. The RMB exchange rate will maintain two-way fluctuations next year, and it is no longer a steady profit for enterprises to hold US dollars and postpone foreign exchange settlement. While stabilizing domestic foreign trade and foreign investment, continuing to expand high-level opening-up and expanding domestic demand in an all-round way implies the certainty of economic stabilization and recovery, which is expected to promote the return of short-term securities investment and medium-and long-term direct investment and help the RMB stop falling and rebound.Aviation Materials Co., Ltd. released the Procurement Project of Feasibility Study Report of Beijing Aviation Materials Research Institute Co., Ltd., and China Hangfa Online Mall released the Project of Feasibility Study Report of Beijing Aviation Materials Research Institute Co., Ltd.. The publishing unit is Beijing Institute of Aeronautical Materials Co., Ltd. (Aeronautical Materials Co., Ltd., 688563). Services include: feasibility study report of equity acquisition project; Feasibility study report on technology patent acquisition.Lingang Daya Auto Parts Intelligent Manufacturing Base Project officially started. On the morning of December 12th, the groundbreaking ceremony of Lingang Daya Auto Parts Intelligent Manufacturing Base Project was held in Shanghai Lingang Fengxian Park. After the completion of the project, two 3500T/2500T high-speed multi-position stamping lines are designed, with an annual production capacity of 11 million pieces; Design 210 connection workstations such as spot welding/arc welding/projection welding/riveting, with an annual production capacity of 4 million sets of sheet metal parts; Design an intelligent logistics and three-dimensional warehouse.

Jinmo Technology: The reserve price for the transfer of 40% equity of Mo Tian Jun Fu is 9,980,600 yuan. Jinmo Technology announced that the company held the 28th meeting of the 4th Board of Directors on November 29th, 2024, and reviewed and approved the Proposal on Authorizing the General Manager's Office to Transfer the Equity of Joint Venture. Authorized by the resolution of the board of directors, the company entrusted Southwest United Assets and Equity Exchange to publicly list and transfer 40% equity of Beijing Mo Tian Jun Fu Private Equity Fund Management Co., Ltd., with a reserve price of 9,980,600 yuan. Aerofilm Technology Development Group Co., Ltd. became the final transferee, with a transaction price of 9,980,600 yuan. Aerofilm Technology holds 23.63% shares of Jinmo Technology, which is the controlling shareholder of the company and also the shareholder holding more than 5% shares. This transaction constitutes a connected transaction.IEA monthly report: global oil inventories rebounded in November. OECD crude oil inventories fell by 30.9 million barrels in October. It was observed that global oil inventories fell by 39.3 million barrels in October.Rapdidus will start producing 2-nanometer chips in April next year. Dong Zhelang, president of Rapdidus, an advanced Japanese semiconductor foundry company, said that by the end of March 2025, Rapdidus will complete all the equipment setup required for trial production of 2-nanometer chips, and start the trial production line in April to actually produce 2-nanometer chips.

Reuters survey: In December, the Bank of England decided to keep interest rates unchanged or cut interest rates by 100 basis points next year. All 71 economists surveyed during December 6-11 predicted that the Bank of England would keep its target interest rate unchanged at 4.75% at its meeting on December 19. Among the economists who predict the interest rate outlook until the end of 2025, about 54% (36 out of 67) expect to cut interest rates by 100 basis points by the end of next year, another 17 expect to cut interest rates by at least 125 basis points, and 14 expect to cut interest rates by at most 75 basis points.Dashengda and Tuopai Shede Group set up investment partnerships. According to the enterprise search APP, Sichuan Fujiang Yingke Investment Partnership (Limited Partnership) was recently established with a capital contribution of 200 million yuan. Its business scope includes: asset management services invested by its own funds; Enterprise management consulting; Information technology consulting service. Enterprise equity penetration shows that the enterprise is jointly held by Dashengda and Sichuan Tuopai Shede Group Co., Ltd..Qianjin Pharmaceutical Co., Ltd.: The subsidiary company obtained the dapoxetine hydrochloride Pharmaceutical Registration Certificate, and Qianjin Pharmaceutical announced that Qianjin Xiangjiang Pharmaceutical Co., Ltd. received the dapoxetine hydrochloride Pharmaceutical Registration Certificate approved and issued by National Medical Products Administration. The medicine is suitable for the treatment of male premature ejaculation patients aged 18 to 64.